Archives

Opus Fund Services Discusses the Elevation of Operational Due Diligence with Channel Diligence’s Co-Founder Stephanie Sirois

B Newest episode of “The Opus Open Kitchen” podcast features insights on how fund managers can capitalize on evolving due diligence trends NEW YORK, April… Login to continue reading Login…

Read MoreOpus Fund Services Discusses the Elevation of Operational Due Diligence with Channel Diligence’s Co-Founder Stephanie Sirois

A peek into “Made in China” from ZXMOTO: entrepreneurial drive, innovation, and industrial strength — all indispensable

B BEIJING, April 17, 2026 /PRNewswire/ — A news report from China.org.cn on ZXMOTO’s victory and “Made in China”: In the hit Chinese movie series “Pegasus,”… Login to continue reading Login…

Read MoreA peek into “Made in China” from ZXMOTO: entrepreneurial drive, innovation, and industrial strength — all indispensable

L’Oréal Paris and Ulta Beauty Unveil “Mother & ___” Campaign: A Celebration of the Limitless Worth and Multifaceted Identities of Motherhood

B The nationwide retail and social campaign will honor the multifaceted identities of women beyond the title of Mom NEW YORK, April 17, 2026 /PRNewswire/… Login to continue reading Login…

Read MoreL’Oréal Paris and Ulta Beauty Unveil “Mother & ___” Campaign: A Celebration of the Limitless Worth and Multifaceted Identities of Motherhood

MONDAY DEADLINE: Berger Montague Advises NuScale Power Corporation (NYSE: SMR) Investors to Inquire About a Securities Fraud Class Action by April 20, 2026

B PHILADELPHIA, April 17, 2026 /PRNewswire/ — National plaintiffs’ law firm Berger Montague PC announces that a class action lawsuit has been filed against NuScale… Login to continue reading Login…

Read MoreMONDAY DEADLINE: Berger Montague Advises NuScale Power Corporation (NYSE: SMR) Investors to Inquire About a Securities Fraud Class Action by April 20, 2026

Marengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026

B Encouraging Phase 2 clinical activity with confirmed complete responses observed in heavily pretreated metastatic breast cancer across both TNBC and HR+/HER2- subtypes First public… Login to continue reading Login…

Read MoreMarengo Reports Late-Breaking Initial Phase 2 Clinical Results from Invikafusp Alfa Plus TRODELVY® and Unveils Partnered Novel IPN01203/STAR0501 STAR Program in Phase 1 at AACR 2026